

SHL/SEC/2020

October 23, 2020

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Company Code: 537253

Dear Sir/Ma'am,

Sub. : **Outcome of the 242nd Board Meeting held on 23.10.2020.**


Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Friday October 23, 2020, the meeting was started at 03:30 p.m. and concluded at 5.11p.m.

- 1. Approved Unaudited Financial Results (consolidated) for the Second quarter/six months ended September 30, 2020 of the Financial Year 2020-21 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).**

You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,
for **Sunil Healthcare Limited**


Santosh Kumar Sharma
Company Secretary
FCS-6817
Encl : As above

23/10/2020
Handwritten signature
5:20 P.M.

Page 1 of 1



SUNIL HEALTHCARE LIMITED

Registered Office,
88/252-A, Vyas Tower, Shahpurji,
New Delhi-110049

Email: info@sunilhealthcare.com, website: www.sunilhealthcare.com

CIN : L24302DL1973PL189642

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2020

₹ in Lakhs

Particulars	Standalone						Consolidated						
	Quarter ended			Half Year Ended			Year Ended	Quarter ended			Half Year Ended		
	30th September 2020	30th June 2020	30th September 2019	30th September 2020	30th September 2019	31st March 2020	30th September 2020	30th June 2020	30th September 2019	30th September 2020	30th September 2019	31st March 2020	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Revenue from Operations	2,267.24	2,500.18	1,705.13	4,367.42	3,553.92	7,012.89	2,285.04	2,363.40	1,670.94	4,448.44	1,488.32	7,002.12	
2 Other Income	52.54	14.44	1,198.09	87.28	1,204.00	1,497.77	66.10	13.02	1,193.77	79.12	1,205.85	1,467.86	
3 Total Income (1+2)	2,320.08	2,514.62	2,903.22	4,454.70	4,757.92	8,510.70	2,351.14	2,376.42	2,864.71	4,527.56	4,694.17	8,469.98	
4 Expenses													
a) Cost of Materials consumed	790.10	649.54	984.40	1,439.64	1,304.24	3,547.51	790.10	649.54	999.50	1,439.64	1,904.24	3,547.52	
b) Purchase of Stock-in-trade	-	-	-	-	-	0.24	-	-	-	-	-	0.24	
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	130.09	337.70	(206.22)	467.79	(502.35)	(637.41)	122.57	351.64	(251.65)	474.21	(584.08)	(736.87)	
d) Employee benefit expenses	311.79	308.88	316.08	620.67	632.22	1,301.74	311.79	308.88	316.08	620.67	632.22	1,301.74	
e) Finance Costs	144.25	146.57	180.15	290.82	354.04	895.43	144.25	146.57	181.42	290.82	354.56	895.43	
f) Depreciation and amortisation	154.04	151.64	147.87	305.68	294.44	612.69	154.04	151.65	147.91	305.71	294.51	612.82	
g) Other Expenses	792.65	518.65	1,551.72	1,301.30	2,195.48	3,232.32	812.63	586.04	1,579.92	1,398.67	2,271.85	3,349.04	
Total Expenses	2,912.92	2,112.98	2,974.00	4,425.90	4,878.27	8,732.52	2,335.40	2,194.32	2,973.18	4,529.72	4,875.30	8,769.94	
5 Profit before tax from Continuing Operation(3-4)	7.16	1.64	(70.78)	8.80	(120.35)	(221.82)	15.74	(17.90)	(108.47)	(2.16)	(181.13)	(299.96)	
6 Tax Expenses (Net)	0.91	1.58	-	2.49	-	(65.00)	1.74	2.07	0.93	3.81	0.93	(63.40)	
a) Current Tax	-	-	-	-	-	-	0.83	0.49	0.93	1.32	0.93	1.60	
b) Deferred Tax Charged/(Credit)	0.91	1.58	-	2.49	-	(65.00)	0.91	1.58	-	2.49	-	(65.00)	
7 Profit/(Loss) after tax from Continuing Operation	6.25	0.06	(70.78)	6.31	(120.35)	(156.82)	14.00	(19.97)	(109.40)	(5.97)	(182.06)	(236.54)	
8 Profit/(Loss) before tax from Discontinued Operations	-	-	7.63	-	6.54	(259.94)	-	-	7.63	-	6.54	(259.94)	
Tax expenses from Discontinued Operations	-	-	-	-	-	(100.14)	-	-	-	-	-	(100.14)	
Profit/(Loss) after tax from Discontinued Operations	-	-	7.63	-	6.54	(259.80)	-	-	7.63	-	6.54	(259.80)	
9 Profit/(Loss) after tax	6.25	0.06	(63.15)	6.31	(113.81)	(146.62)	14.00	(19.97)	(101.77)	(5.97)	(175.52)	(496.36)	
10 Other Comprehensive Income (OCI)	-	-	-	-	-	280.42	1.20	(1.71)	10.88	(0.51)	1.09	280.42	
a) Items that will not be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	280.42	-	-	-	-	-	280.42	
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	1.20	(1.71)	10.88	(0.51)	1.09	(3.36)	
11 Total Comprehensive Income	6.25	0.06	(63.15)	6.31	(113.81)	(136.20)	15.20	(21.68)	(90.89)	(6.48)	(174.43)	(219.30)	
12 Paid-up equity share capital (Face value per share ₹10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	
13 Other Equity	-	-	-	-	-	3,752.27	-	-	-	-	-	3,434.35	
14 Earning per share of ₹ 10/- each(not annualised)(Continuing Operation)													
(a) Basic (₹)	0.06	0.00	(0.69)	0.06	(1.17)	(1.53)	0.14	(0.19)	(1.07)	(0.06)	(1.78)	(2.31)	
(b) Diluted (₹)	0.06	0.00	(0.69)	0.06	(1.17)	(1.53)	0.14	(0.19)	(1.07)	(0.06)	(1.78)	(2.31)	
Earning per share of ₹ 10/- each(not annualised)(Discontinued Operation)													
(a) Basic (₹)	-	-	0.07	-	0.06	(2.53)	-	-	0.07	-	0.06	(2.53)	
(b) Diluted (₹)	-	-	0.07	-	0.06	(2.53)	-	-	0.07	-	0.06	(2.53)	
Earning per share of ₹ 10/- each(not annualised)													
(a) Basic (₹)	0.06	0.00	(0.62)	0.06	(1.11)	(4.06)	0.14	(0.19)	(0.99)	(0.06)	(1.71)	(4.84)	
(b) Diluted (₹)	0.06	0.00	(0.62)	0.06	(1.11)	(4.06)	0.14	(0.19)	(0.99)	(0.06)	(1.71)	(4.84)	

Pratim

₹ in Lakhs

Cash Flow Statement

Particulars	Standalone		Consolidated	
	For the Half	For the Half	For the Half	For the Half
	Year Ended 30th	Year Ended 30th	Year Ended 30th	Year Ended
	Sep. 2020	Sep. 2019	Sep. 2020	30th Sep. 2019
	Unaudited	Unaudited	Unaudited	Unaudited
A. Cash Flow from Operating Activities				
Profit before Tax from continued business	8.80	(113.81)	(2.14)	(174.59)
Profit before Tax from discontinued business				
Adjustment for:				
Finance Costs	290.82	354.04	290.82	354.56
Depreciation and Amortization Expenses	305.68	294.44	305.71	294.51
(Profit)/Loss on Sales/Discontinued of Property, Plant and Equipment	3.84	(0.03)	3.84	(0.03)
Interest Income	(13.02)	(15.43)	(13.02)	(15.41)
Fair valuation of investments	(0.39)	(0.18)	(0.59)	(0.18)
Provision for loss allowance	-	706.11	-	706.11
Gain on fair valuation of Redeemable preference share	-	(1,097.03)	-	(1,097.03)
Liabilities/Provisions no longer required written back	1.97	(9.28)	(4.04)	(9.28)
Unrealised (gain)/loss foreign currency transactions and translation	(2.01)	(27.92)	(5.89)	(29.27)
Operating profit before working capital changes	595.65	80.93	574.67	21.39
Changes in working Capital:				
(Increase)/Decrease in Inventories	497.65	(541.58)	503.08	(641.55)
(Increase)/Decrease in Trade and other Receivables	(81.20)	254.83	(255.44)	421.14
Increase /Decrease in Trade and other payable	(768.60)	266.86	(574.72)	254.55
Cash generation from Operation	243.54	53.04	247.59	55.59
Payment of Direct Taxes	(1.48)	(6.39)	(2.80)	(15.00)
Net Cash generated/ (used) - Operating Activities	241.86	46.65	244.79	40.53
B. Cash Flow from Investing Activities				
Purchase of Property, Plant and Equipment & Intangible Assets	(279.15)	(3.92)	(279.15)	(3.92)
Sale of Property, Plant and Equipment	1.88	4.20	1.88	10.14
Movement in Term Deposits	(7.42)	(4.75)	(7.42)	(4.75)
Interest Received	14.79	13.96	14.79	11.56
Net Cash Generated/ (Used) - Investing Activities	(269.90)	9.49	(269.90)	13.03
C. Cash Flow from Financing Activities				
Receipts from Non Current Borrowings	131.82	80.00	131.82	80.00
Repayment of Non Current Borrowings	(133.52)	(148.80)	(133.52)	(148.80)
Loan from Director	-	267.00	-	267.00
Receipts/(Repayment) of Short-term Borrowings (Net)	785.85	(220.82)	785.85	(220.82)
Payment of lease liability	(7.85)	-	(7.85)	-
Receipts on issuance of Redeemable Preference shares	-	1,165.00	-	1,165.00
Finance Cost Paid	(141.82)	(167.16)	(141.82)	(174.41)
Net Cash Generated/ (Used) - Financing Activities	634.48	555.22	634.48	547.95
Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)	606.44	611.36	609.37	601.51
Add - Opening Cash and Cash Equivalents	116.48	98.43	134.05	110.97
Closing Cash and Cash Equivalents	722.92	709.79	743.42	712.48

4. COVID - 19 pandemic has caused serious disruption on the global economic and business environment. There is a huge uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these financial results on the carrying value of its assets and liabilities as on 30.09.2020. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of these assets and to discharge its obligation as adequate liquidity is available. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.
5. Consequent to decision taken by Board of Directors to phase out "marketing of Food product" in previous year. Accordingly, the Company has ceased from marketing of food products and losses of the discontinued business has been disclosed under "Profit/(Loss) from discontinued operations" separately. At the quarter end, the Company has no liability to be paid and no assets to realise related to this business.
6. The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.
7. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on October 23, 2020.

Place: NEW DELHI
Date: 23-10-2020


Anil Khaitan
[Chairman cum Managing Director]
DIN: 00719951

Statement of Assets and Liabilities

Particulars	Standalone		Consolidated	
	As at 30th Sep. 2020	As at 31st March 2020	As at 30th Sep. 2020	As at 31st March 2020
	Un-audited	Audited	Un-audited	Audited
A ASSETS				
1 Non Current Assets				
(a) Fixed Assets				
(i) Property, Plant and Equipment	5402.99	5,544.80	5403.12	5,544.95
(ii) Capital Work-in-Progress	0.69	0.69	0.69	0.69
(iii) Right of Use Assets	1419.69	1,427.31	1419.69	1,427.31
(iv) Other Intangible Assets	22.5	24.95	22.5	24.95
(b) Financial Assets				
(i) Investment	24.43	23.83	11.42	10.82
(ii) Loans	93.65	93.89	93.65	93.89
(c) Other non-current Assets	7.96	7.96	7.96	7.96
2 Current Assets				
(a) Inventories	1745.77	2,243.41	1982.78	2,485.86
(b) Financial Assets				
(i) Loan	29.52	30.16	-	-
(ii) Trade Receivables	2855.65	2,863.05	2513.4	2,355.54
(iii) Cash and Cash Equivalents	722.92	116.48	743.42	134.05
(iv) Other Bank Balances	380.77	373.35	380.77	373.35
(v) Other Financial Assets	168.16	169.77	41.81	40.69
(c) Current Tax Assets	40.55	39.07	40.55	39.69
(d) Other Current Assets	547.1	482.46	556.32	482.88
TOTAL ASSETS	13,462.35	13,441.18	13,218.28	13,022.65
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity Share Capital	1,025.48	1,025.48	1,025.48	1,025.48
(b) Other Equity	8758.58	3,752.27	3,427.87	3434.35
2 Non Current Liabilities				
(a) Financial Liabilities- Borrowings	1105.32	1,202.91	1105.32	1,202.91
(b) Provisions	195.75	181.96	195.75	181.96
(c) Deferred Tax Liabilities (Net)	554.01	551.52	554.01	551.52
3 Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	4018.12	3,232.27	4018.12	3,232.27
(ii) Trade Payables	-	-	-	-
Total Outstanding dues of Micro enterprises and small enterprises	62.85	79.70	62.85	79.70
Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	1563.92	2,275.40	1552.97	2174.86
(iii) Lease Liabilities	5.45	13.30	5.45	13.30
(iv) Other Financial Liabilities	901.68	776.41	901.68	776.41
(b) Other Current Liabilities	160.85	239.42	257.26	237.75
(c) Provisions	110.54	110.54	110.54	110.54
(d) Current tax liabilities(Net)	-	-	0.98	1.6
TOTAL - EQUITY AND LIABILITIES	13,462.35	13,441.18	13,218.28	13,022.65



JKVS & CO.

Chartered Accountants

Review Report on unaudited standalone quarterly and half yearly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2020. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: New Delhi
Date: October 23, 2020

For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E

Sajal
Sajal Goyal
Partner

Membership No.523903

UDIN: 20523903AAAA BX 7410

JKVS & CO.

Chartered Accountants

Independent Auditor's Review Report on consolidated unaudited quarterly and half yearly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2020, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities
 - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
 - b. Sunil Healthcare North America LLC (Incorporated in USA)



JKVS & CO.

Chartered Accountants

Review Report on unaudited standalone quarterly and half yearly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2020. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: New Delhi
Date: October 23, 2020

For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E


Sajal Goyal
Partner

Membership No.523903

UDIN: 20523903AAAA BX 7410